POST Online Media Lite Edition


Fresenius Kabi to acquire Akorn for $34 per share

Staff Writer |
Fresenius Kabi has agreed to acquire Akorn, a U.S.-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.

Article continues below

The price is approximately $4.3 billion, or $34.00 a share, plus the assumption of approximately $450 million of debt.

The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and EPS, excluding integration costs.

The agreement and transaction have been approved by the boards of both companies and will be recommended by Akorn’s board to its shareholders.

Akorn’s largest shareholder has committed to supporting the transaction.

The transaction is subject to approval by Akorn shareholders and other customary closing conditions, including regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act.

What to read next

Akorn to buy VPI Holdings for $440m
Fresenius Medical Care to invest $140 million, employ 665
FTC: Akorn Enterprises' acquisition of Hi-Tech Pharmacal anticompetitive